19.04.2024 • News

Linde to Build New Electrolyzer Plant in Brazil

Linde announced that – through its subsidiary White Martins – will build, own and operate a second 5-MW pressurized alkaline electrolyzer to produce green hydrogen in Jacareí, São Paulo, Brazil. Start-up of the facility is expected in 2025.

The new plant is to be located next to the company’s existing air separation facility and will be powered by renewable energy from local solar and wind power projects to produce independently certified green hydrogen, Linde said.

Once the new White Martins plant is up and running, it will supply green hydrogen to the glass manufacturer Cebrace, also based in Jacareí, as well as to other customers in the metal, food and chemical industries, among others.

According to Linde, White Martins was the first company to produce green hydrogen on an industrial scale in South America at its plant in Pernambuco in 2022.

“Investing in green hydrogen to supply the industrial heart of São Paulo reaffirms our commitment to the energy transition in Brazil,” said Gilney Bastos, Linde’s president South Latin America. “We look forward to helping Cebrace achieve its decarbonization goals while also supporting merchant customers’ transition to lower carbon solutions,” Bastos added.

Source: Linde
Source: Linde

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read